COMPANY PROFILE

Stipple Bio

Explore full profile

Precision oncology via the Pointillist Platform for tumor-specific epitopes

Cambridge, United StatesFounded 2022Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Stipple Bio

Stipple Bio is a Cambridge, Massachusetts biotechnology company that uses its Pointillist Platform to identify tumor-specific cell-surface epitopes and develop precision oncology medicines with a higher therapeutic index across modalities such as ADCs, T-cell engagers and radiopharmaceuticals. Founded by cancer biologists Dr Aaron Ring (Fred Hutch) and Dr Aashish Manglik (UCSF) and led by CEO Jeff Landau, Stipple’s lead candidate STP-100 is a novel ADC designed to avoid on-target/off-tumor toxicity and is expected to enter clinical studies in early 2027. In April 2026 Stipple emerged from stealth with an oversubscribed $100 million Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest, with Emerson Collective Investments (Yosemite), GV, LoLa Capital Partners and GordonMD Global Investments, to advance STP-100 into early clinical studies and expand the pipeline. Sources: Stipple Bio 6 Apr 2026.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Cambridge, United States
Employees: 13
Open positions: 6
Dealroom signal: 88.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Verified Unicorns and $1B Exits, AI Drug Discovery, Techbio, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Apr 2026	$100M	$2.2B	GV · GordonMD Global Investment · Nextech Invest · a16z Bio + Health	↗
EARLY VCOther financing	Dec 2024	$9.5M	$38M	Undisclosed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Stipple Bio website traffic

Latest recorded traffic for Stipple Bio is 4.3K monthly website visits, up 53.6% over the last three months. Stipple Bio's team grew 116.7% over the past year.

Latest monthly visits4.3K 3-month web change+53.6% 1-year team growth+116.7%

Monthly website visitsFeb 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

VP, Biotherapeutics DiscoveryCambridge, MA · Other · Aug 26, 2026 Research Associate II, Cancer BiologyCambridge, MA · Other · Jun 21, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OWOwkinCollaborative research platform and unique AI drug development solutions that make precision medicine a reality	Paris, France	Operational	425	$368M	$1B
ILiLoFAI and photonics platform for personalized drug discovery.	London, United Kingdom	Operational
OBOrionis BiosciencesPioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities	Waltham, United States	Operational
KUKuanoUsing machine learning and quantum physics to simulate, filter, and discover new molecules	Cambridge, United Kingdom	Operational
PAPanakeiaUniversal engine for accelerating cancer diagnosis and enabling precision treatment	Cambridge, United Kingdom	Operational
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational
RGReveal GenomicsDeveloping tests that harness the full potential of comprehensive genetic and clinical data for each patient	Barcelona, Spain	Operational
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational